Work Here?
About Abata Therapeutics
Industries
Biotechnology
Company Size
11-50
Company Stage
Early VC
Total Funding
$190M
Headquarters
Cambridge, Massachusetts
Founded
2021
Overview
Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Abata stands out in the biotech market by targeting a specific niche of autoimmune disease patients and forming strategic partnerships, such as with ElevateBio, to enhance their research and manufacturing capabilities. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.
💡 Want to apply to Abata Therapeutics?
You have ways to get a Abata Therapeutics referral from your network.
Get referrals →
Simplify's Take
What believers are saying
- Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
- FDA's accelerated approval pathways may expedite Abata's clinical trials.
- Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.
What critics are saying
- Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
- Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
- Rising clinical trial costs pose financial risks to Abata's pipeline progression.
What makes Abata Therapeutics unique
- Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
- Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
- Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$190M
Above
Industry Average
Funded Over
2 Rounds
Lightspeed Venture PartnersGrowth & Insights and Company News
6 month growth
↑ 17%1 year growth
↑ 22%2 year growth
↑ 22%WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) - Abata Therapeutics, a clinical-stage biotech company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced the appointment of Joanne Beck, Ph.D., as chief technical officer.
WATERTOWN, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) — Abata Therapeutics, a company focused on transforming lives with Treg therapies for... Read More
Founded by pioneers in Treg biology, TCR and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable.
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard "Lenny" Dragone, M.D., Ph.D., as its new chief medical officer.
Abata has collaborated with ElevateBio BaseCamp to develop a manufacturing process that engineers and grows Tregs for therapeutic use.
There are no jobs for Abata Therapeutics right now.
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Abata Therapeutics
About Abata Therapeutics
Industries
Biotechnology
Company Size
11-50
Company Stage
Early VC
Total Funding
$190M
Headquarters
Cambridge, Massachusetts
Founded
2021
There are no jobs for Abata Therapeutics right now.
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Abata Therapeutics